Preliminary results of a phase II study to evaluate the efficacy and safety of disitamab vedotin (RC48-ADC) in combination with radiotherapy for adjuvant therapy in upper tract urothelial carcinoma.

Authors: Zihao Tao, Xuanjun Guo, Chunru Xu, Xiaoying Li, Qi Tang, Xuesong Li

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e16583

Source: Full article

e16583